Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan

BACKGROUND: This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients. METHODS: A clinical pilot study was designed in which patients with ulcer and/or pain at rest were treated with bosentan p.o. at a dose of 62.5...

Descripción completa

Detalles Bibliográficos
Autores principales: De Haro, Joaquin, Acin, Francisco, Bleda, Silvia, Varela, Cesar, Esparza, Leticia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306190/
https://www.ncbi.nlm.nih.gov/pubmed/22333218
http://dx.doi.org/10.1186/1471-2261-12-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306190/
https://www.ncbi.nlm.nih.gov/pubmed/22333218
http://dx.doi.org/10.1186/1471-2261-12-5

Ejemplares similares